TY - JOUR
T1 - Giant cell tumors of the sacrum-a nationwide study on midterm results in 26 patients after intralesional excision
AU - van der Heijden, L.
AU - van der Sande, M.
AU - van der Geest, I.
AU - Schreuder, H.
AU - van Royen, B.
AU - Jutte, P.
AU - Bramer, J.
AU - Oner, F.
AU - van Noort-Suijdendorp, A.
AU - Kroon, H.
AU - Dijkstra, P.
PY - 2014
Y1 - 2014
N2 - Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT). We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U. Recurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024). Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function
AB - Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT). We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U. Recurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024). Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function
U2 - https://doi.org/10.1007/s00586-014-3263-5
DO - https://doi.org/10.1007/s00586-014-3263-5
M3 - Article
C2 - 24614982
SN - 0940-6719
VL - 23
SP - 1949
EP - 1962
JO - European Spine Journal
JF - European Spine Journal
IS - 9
ER -